🇺🇸 FDA
Pipeline program

Imsidolimab

ANB019-207

Phase 2 mab terminated

Quick answer

Imsidolimab for Acneiform Eruptions is a Phase 2 program (mab) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Vanda Pharmaceuticals
Indication
Acneiform Eruptions
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials